Clinical Trials
74 trialsAndrogen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
University of California, Davis
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Dana-Farber Cancer Institute
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Mayo Clinic
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
University of Cincinnati
I-SPY
QuantumLeap Healthcare Collaborative
KNIGHTS
University of Maryland, Baltimore
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
ANALLISA
MedSIR
NIRVANA-1
ARCAGY/ GINECO GROUP
HARMONY
Hoosier Cancer Research Network
Niraparib in Patients With Pancreatic Cancer
Dana-Farber Cancer Institute
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Abramson Cancer Center at Penn Medicine
PARPi-PANC
Centre Leon Berard
STAR
University of Oklahoma
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
M.D. Anderson Cancer Center
Niraparib in Tumors Metastatic to the CNS
Massachusetts General Hospital
Niraparib/TTFields in GBM
Abramson Cancer Center at Penn Medicine
NIPAVect
Emory University
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
Memorial Sloan Kettering Cancer Center
NADiR
Massachusetts General Hospital
REPRESENTATION
Latin American Cooperative Oncology Group
ParpVax2
Abramson Cancer Center at Penn Medicine
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
Northwell Health
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Mayo Clinic
ProTarget
Rigshospitalet, Denmark
EUDARIO
Universitaire Ziekenhuizen KU Leuven
OU-SCC-PI-4G
University of Oklahoma
NERO
University Hospital Southampton NHS Foundation Trust
SOPRANO
Institute of Cancer Research, United Kingdom
Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
University of Oklahoma
PLATFORM Study of Precision Medicine for Rare Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
University of Pittsburgh
Newton
Mario Negri Institute for Pharmacological Research
Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Tongji Hospital
GUNS
University of British Columbia
MEGALiT
Uppsala University Hospital
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
Hoosier Cancer Research Network
IMPRESS-N
Oslo University Hospital
LUZERN
MedSIR
Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency
Korea University Anam Hospital
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
University Health Network, Toronto
DRUP
The Netherlands Cancer Institute
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Shandong University
NEOPRIMA
The University of Hong Kong